NCT00067470
MPS VI, Mucopolysaccharidosis VI
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The purpose of the study is to evaluate the ability of rhASB versus placebo to enhance endurance in patients with Mucopolysaccharidosis VI (MPS VI), as evidenced by an increase in the number of meters walked in the 12 minute walk test at Week 24 compared with baseline.
All
From 7 Years
No
Placebo, N-acetylgalactosamine 4-sulfatase
Phase 3
Interventional
39
2003-09
2009-12-24
Novato, California, United States
Inclusion Criteria
Exclusion Criteria
*required fields
"*" indicates required fields